Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957324 | 0.93 | USP25 (1.00) | USP25USP28 | |
| SCHEMBL22957320 | 0.91 | USP25 (1.00) | USP25USP28 | |
| SCHEMBL24592897 | 0.90 | USP25 (0.81) | USP25USP28 | |
| SCHEMBL22957443 | 0.89 | USP25 (1.00) | USP25USP28 | |
| SCHEMBL22957278 | 0.88 | USP25 (1.00) | USP25USP28 | |
| SCHEMBL22957568 | 0.86 | USP25 (1.00) | USP25USP28 | |
| SCHEMBL22957398 | 0.85 | USP28 (1.00) | USP25USP28 | |
| SCHEMBL22957253 | 0.85 | USP25 (0.82) | USP25USP28 | |
| SCHEMBL22957326 | 0.84 | USP25 (1.00) | USP25USP28 | |
| SCHEMBL22957256 | 0.84 | USP28 (0.85) | USP25USP28 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3414252-B1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | USP25 2/4885USP28 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.